Method and apparatus for determining the cerebral state of a patient with fast response

• US 6,731,975 B1
• Filed: 10/16/2000
• Issued: 05/04/2004
• Est. Priority Date: 10/16/2000
• Status: Expired due to Term

• Current Assignee: Instrumentarium Dental Incorporated (Envista Holdings Corporation)
• Original Assignee: Instrumentarium Dental Incorporated (Envista Holdings Corporation)
• Inventors: Viertiö-Oja, Hanna E., Rantala, Borje T.
• Primary Examiner(s): Hindenburg, Max F.
• Assistant Examiner(s): MALLARI, PATRICIA C
• Application Number:
  US09/688,891
• Time in Patent Office: 1,296 Days
• Field of Search: 600/544-546
• US Class Current: 600/544
• CPC Class Codes: A61B 5/16 Devices for psychotechnics using teaching or educational appliances G09B1/00 - G09B7/00; Testing reaction times ; Devices for evaluating the psychological state
• CPC Class Codes: A61B 5/316 Modalities, i.e. specific diagnostic methods
• CPC Class Codes: A61B 5/369 Electroencephalography [EEG] devices for psychotechnics A61B5/16
• CPC Class Codes: A61B 5/389 Electromyography [EMG]
• CPC Class Codes: A61B 5/4821 Determining level or depth of anaesthesia A61B5/1106 takes precedence
• CPC Class Codes: A61B 5/7203 for noise prevention, reduction or removal
• CPC Class Codes: A61B 5/7257 using Fourier transforms
• CPC Class Codes: A61B 5/726 using Wavelet transforms
• CPC Class Codes: G06F 2218/08 Feature extraction

Abstract

A method and apparatus for ascertaining the cerebral state of a patient. The method/apparatus may find use in ascertaining the depth of anesthesia of the patient. In one embodiment, the entropy of the patient'"'"'s EEG signal data is determined as an indication of the cerebral state. A frequency domain power spectrum quantity is obtained from the patient'"'"'s EMG signal data. The latter quantity can be updated more frequently than the EEG entropy due to its higher frequency. The EEG entropy indication and the EMG power spectrum indication can be combined into a composite indicator that provides an immediate indication of changes in the cerebral state of the patient. In another embodiment, the frequency range over which the entropy of the biopotential signal from the patient is determined is broadened to encompass both EEG signal data and EMG signal data and the entropy so determined used as an indication of the patient'"'"'s cerebral state.

Claims

1. Apparatus for ascertaining the cerebral state of a patient, including a state resulting from the administration of a drug, said apparatus comprising:

(a) means for obtaining biopotential signals from the patient, the biopotential signals containing EEG signal data and EMG signal data, the EMG signal data being primarily of a higher frequency than the EEG signal data which is primarily of a lower frequency;

(b) means for analyzing a sample of sequential signal data over a frequency range that is sufficiently wide to include both the EEG and EMG signal data to obtain a measure of the complexity of the signal data, said analyzing means using a length of EEG signal data and effectively using a EMG signal data sample of shorter length than the EEG signal data sample; and

(c) means providing the complexity measure as an indicator of the cerebral state of the patient, said providing means updating said indicator at a repetition rate allowed by a shorter sample length of the EMG signal data to indicate changes in the cerebral state of the patient.

2. The apparatus according to claim 1 wherein said analyzing means is further defined as analyzing the signal data over a frequency range extending from a frequency of about 0.5 Hz to a frequency which is above 32 Hz.

3. The apparatus according to claim 1 or claim 2 wherein said analyzing means if further defined as obtaining a Lempel-Ziv complexity measure of the signal data.

4. The apparatus according to claim 1 or claim 2 wherein said analyzing means further analyzes EEG signal data to obtain a complexity measure of the EEG signal data and said providing means further provides the complexity measure of the EEG signal data as a further indicator of the cerebral state of the patient.

5. The apparatus according to claim 4 further including means for normalizing the further indication obtained from the analysis of the EEG signal data and the EEG-EMG signal data indication so that the further indication and EEG-EMG indication are equal in the absence of EMG signal data.

6. The apparatus according to claim 1 or claim 2 further defined as including means for notch filtering the signal data to remove power line frequency harmonics.

7. The apparatus according to claim 1 or claim 2 further defined as including means for processing the signal data to detect artifacts.

8. The apparatus according to claim 7 further defined as including means for filtering the signal data to remove artifacts.

9. The apparatus according to claim 2 wherein said analyzing means is further defined as obtaining a measure of the entropy of the signal data.

10. The apparatus according to claim 1 wherein said analyzing means is further defined as obtaining a measure of the entropy of the signal data.

11. The apparatus according to claim 1 or claim 2 or claim 10 further defined as one for ascertaining the hypnotic state of a patient.

12. A method for ascertaining the depth of anesthesia of a patient, said method rapidly indicating changes in the hypnotic state of the patient and comprising the steps of:

(a) obtaining biopotential signals from the patient, the biopotential signals containing EEG signal data and EMG signal data, the EMG signal data being primarily of a higher frequency than the EEG signal data which is primarily of lower frequency;

(b) analyzing a sample of sequential signal data existing in a frequency range extending from a frequency of about 0.5 Hz to a frequency which is above 32 Hz to obtain a measure of the complexity of the signal data, the analysis of the EMG signal data effectively using a sample of shorter length than that of the EEG signal data sample due to the higher frequency of the EMG signal data;

(c) providing the complexity measure as a first indication of the cerebral state of the patient, which indication is suitable for being updated at a repetition rate allowed by a shorter sample length of the EMG signal data to rapidly indicate changes in the cerebral state of the patient;

(d) analyzing a sample of EEG signal data to obtain a complexity measure of the EEG signal data;

(e) providing the complexity measure of the EEG signal data as a second indication of the cerebral state of the patient; and

(f) normalizing the first indication and second indication so that the first indication and second indication are equal in the absence of EMG signal data.

13. A method for ascertaining the cerebral state of a patient, including a state resulting from the administration of a drug, said method rapidly indicating changes in such state and comprising the steps of:

(a) obtaining biopotential signals from the patient, the biopotential signals containing EEG signal data and EMG signal data, the EMG signal data being primarily of a higher frequency than the EEG signal data which is primarily of lower frequency;

(b) analyzing a sample of sequential signal data over a frequency range that is sufficiently wide to include both the EEG and EMG signal data to obtain a measure of the complexity of the signal data, the analysis of the EMG signal data effectively using a sample of shorter length than that of the EEG signal data sample due to the higher frequency of the EMG signal data; and

(c) providing the measure as an indication of the cerebral state of the patient, which indication is suitable for being updated at a repetition rate allowed by a shorter sample length of the EMG signal data to rapidly indicate changes in the cerebral state of the patient.

14. The method according to claim 13 wherein step (b) includes analyzing the biopotential signals over a frequency range extending from a frequency of about 0.5 Hz to a frequency which is above 32 Hz.

15. The method according to claim 14 wherein step (b) includes obtaining a measure of the entropy of the signal data.

16. The method according to claim 15 further defined as one for ascertaining the hypnotic state of a patient.

17. The method according to claim 13 or claim 14 including, prior to analyzing the sample in step (b), the step of subjecting the biopotential signals to spectral decomposition.

18. The method according to claim 17 further defined as carrying out the spectral decomposition by means of a Fourier transform.

19. The method according to claim 17 further defined as carrying out the spectral decomposition by employing a set of basis functions other than a Fourier set of functions.

20. The method according to claim 19 further defined as carrying out the spectral decomposition by employing a set of basic functions corresponding to wavelet transformation.

21. The method according to claim 13 or claim 14 further defined as repeating steps (b) and (c) to update the indication.

22. The method according to claim 13 or claim 14 further defined as one for ascertaining the hypnotic state of a patient.

23. The method according to claim 22 further defined as repeating steps (b) and (c) to update the indication.

24. The method according to claim 22 further defined as repeating steps (b) and (c) to update the indication at a repetition rate allowed by a shorter sample length of the EMG signal data.

25. The method according to claim 14 further defined as one for ascertaining the hypnotic state of a patient.

26. The method according to claim 13 or claim 14 further defined as in including the steps of analyzing a sample of the EEG signal data to obtain a complexity measure of the EEG signal data and providing the complexity measure of the EEG signal data as a further indication of the cerebral state of the patient.

27. The method according to claim 26 further defined as including the step of normalizing the further indication obtained from the analysis of the EEG signal data and the EEG-EMG signal data indication so that the further indication and EEG-EMG indication are equal in the absence of EMG signal data.

28. The method according to claim 27 including carrying out the normalizing by multiplying the complexity measure of the EEG signal data by a quantity comprising the logarithm of the number of frequency components used for computations for the EEG signal data complexity measure divided by the logarithm of the number of frequency components used for the computations for the combined EEG-EMG complexity measure.

29. The method according to claim 27 further defined as applying a constant to the normalized indications to maintain the normalization.

30. The method according to claim 13 or claim 14 further defined as including the step of notch filtering to remove power line frequency harmonics.

31. The method according to claim 13 or claim 14 including obtaining the EEG signal data and the EMG signal data from a common signal source.

32. The method according to claim 31 including obtaining the EEG and EMG signal data from biopotential electrodes applied to the head of the patient.

33. The method according to claim 32 including obtaining at least the EMG signal data from electrodes applied to the forehead of the patient.

34. The method according to claim 13 or claim 14 further defined as processing the biopotential signals or signal data to detect artifacts.

35. The method according to claim 34 further defined as filtering the signal data or biopotential signals to remove artifacts.

36. The method according to claim 34 further defined as preventing the use of signal data or biopotential signals affected by artifacts.

37. The method according to claim 34 further defined as detecting excessive muscle activity in the patient from the biopotential signals or signal data and preventing the use of EEG signal data affected by the muscle activity.

38. The method according to claim 34 further defined as including the step of sensing the presence of electrical energy at electro surgical frequencies and as preventing the use of biopotential signals or signal data affected by such an artifact.

39. The method according to claim 34 further defined as detecting simultaneous spikes in both the EEG signal data and EMG signal data as eye movement artifacts and preventing the use of biopotential signals or signal data affected by such artifacts.

40. The method according to claim 13 or claim 14 further defined as repeating steps (b) and (c) to update the indication at a repetition rate allowed by a shorter sample length of the EMG signal data.

41. The method according to claim 13 wherein step (b) includes obtaining a measure of the entropy of the signal data.

42. The method according to claim 41 or claim 15 wherein step (b) includes obtaining the spectral entropy of the signal data.

43. The method according to claim 41 or claim 15 wherein step (b) includes obtaining the approximate entropy of the signal data.

44. The method according to claim 41 further defined as one for ascertaining the hypnotic state of a patient.

45. The method according to claim 13 wherein step (b) a includes obtaining a Lempel-Ziv complexity measure of the signal data.

46. A method according to claim 13 wherein step (b) includes obtaining the complexity measure from fractal spectrum analysis.